Researchers from the Institute of Biomedical Engineering at the University of Toronto have developed a novel MRI contrast agent that may enhance the early detection of inflammatory diseases by targeting nitric oxide (NO), a key molecule involved in the body’s immune response. The new agent activates in the presence of NO and provides a bright contrast in T1-weighted MRI scans, potentially allowing clinicians to monitor inflammation more effectively. This approach could eventually help in diagnosing conditions like heart disease, neurodegeneration, and cancer at earlier stages, potentially improving treatment outcomes.